Stockscreener 앱 받기
89.20
4.40%
3.76
시간 외 거래:
89.20
전일 마감가:
$85.44
열려 있는:
$86.84
하루 거래량:
1.36M
Relative Volume:
0.79
시가총액:
$7.40B
수익:
$1.73B
순이익/손실:
$682.64M
주가수익비율:
11.53
EPS:
7.7364
순현금흐름:
$411.18M
1주 성능:
+9.35%
1개월 성능:
+25.69%
6개월 성능:
+15.48%
1년 성능:
+85.91%
1일 변동 폭
$84.76
$89.80
1주일 범위
$80.77
$89.80
52주 변동 폭
$43.17
$89.80
PTC 테라퓨틱스 Stock (PTCT) Company Profile
명칭
Ptc Therapeutics Inc
전화
(908) 222-7000
주소
500 WARREN CORPORATE CENTER DRIVE, WARREN, NJ
Compare PTCT vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PTCT
Ptc Therapeutics Inc
|
89.20 | 7.09B | 1.73B | 682.64M | 411.18M | 7.7364 |
VRTX
Vertex Pharmaceuticals Inc
|
522.25 | 134.41B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
676.23 | 68.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.93 | 57.01B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
321.50 | 41.79B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
190.46 | 40.39B | 742.00K | -1.37B | -1.07B | -7.0731 |
PTC 테라퓨틱스 Stock (PTCT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-10 | 개시 | Raymond James | Outperform |
| 2026-01-28 | 재개 | Barclays | Overweight |
| 2025-12-01 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-10-20 | 개시 | Wells Fargo | Overweight |
| 2025-06-17 | 개시 | Truist | Buy |
| 2025-05-09 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2025-05-07 | 업그레이드 | Citigroup | Sell → Neutral |
| 2025-03-11 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2025-03-07 | 개시 | Scotiabank | Sector Perform |
| 2024-12-13 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-03 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-10-10 | 재개 | Raymond James | Mkt Perform |
| 2024-09-04 | 개시 | Robert W. Baird | Outperform |
| 2024-08-26 | 재개 | UBS | Buy |
| 2024-05-20 | 업그레이드 | Raymond James | Underperform → Mkt Perform |
| 2023-12-19 | 다운그레이드 | Morgan Stanley | Equal-Weight → Underweight |
| 2023-12-08 | 개시 | Wells Fargo | Overweight |
| 2023-10-30 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2023-10-27 | 다운그레이드 | Citigroup | Neutral → Sell |
| 2023-10-06 | 다운그레이드 | Truist | Buy → Hold |
| 2023-09-18 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2023-09-15 | 다운그레이드 | Raymond James | Outperform → Underperform |
| 2023-03-17 | 개시 | SVB Securities | Market Perform |
| 2022-12-14 | 개시 | Goldman | Sell |
| 2022-09-12 | 개시 | Jefferies | Buy |
| 2022-09-09 | 개시 | Morgan Stanley | Equal-Weight |
| 2022-09-01 | 개시 | Citigroup | Buy |
| 2022-04-04 | 재개 | Cantor Fitzgerald | Overweight |
| 2021-10-18 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2021-04-26 | 재개 | Credit Suisse | Neutral |
| 2021-03-29 | 업그레이드 | RBC Capital Mkts | Underperform → Sector Perform |
| 2021-02-12 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2021-01-05 | 업그레이드 | Citigroup | Neutral → Buy |
| 2020-11-30 | 다운그레이드 | RBC Capital Mkts | Sector Perform → Underperform |
| 2020-10-30 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2020-10-28 | 개시 | UBS | Neutral |
| 2020-10-07 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2020-08-25 | 개시 | Raymond James | Outperform |
| 2020-04-09 | 업그레이드 | Citigroup | Neutral → Buy |
| 2020-02-20 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2020-02-20 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2019-11-12 | 개시 | SunTrust | Buy |
| 2019-05-13 | 업그레이드 | BofA/Merrill | Neutral → Buy |
| 2019-04-11 | 개시 | Bernstein | Outperform |
| 2018-10-03 | 업그레이드 | BofA/Merrill | Underperform → Neutral |
| 2018-10-01 | 개시 | Cantor Fitzgerald | Overweight |
| 2018-07-19 | 개시 | Credit Suisse | Outperform |
| 2018-06-18 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2018-04-04 | 다운그레이드 | Barclays | Equal Weight → Underweight |
| 2018-01-29 | 재개 | RBC Capital Mkts | Sector Perform |
| 2017-11-16 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2017-10-26 | 다운그레이드 | BofA/Merrill | Neutral → Underperform |
| 2017-10-09 | 다운그레이드 | JP Morgan | Neutral → Underweight |
모두보기
PTC 테라퓨틱스 주식(PTCT)의 최신 뉴스
PTCT Maintains Rating by RBC Capital -- Price Target Raised to $85 - GuruFocus
Ptc Therapeutics stock hits all-time high of 87.56 USD By Investing.com - Investing.com South Africa
PTC Therapeutics weighs strategy amid rare disease focus - AD HOC NEWS
RBC Capital Adjusts PTC Therapeutics Price Target to $85 From $82, Maintains Sector Perform Rating - Moomoo
Does Triple Russell 2000 Defensive Index Inclusion Reframe PTC Therapeutics’ Risk Profile And Rare-Disease Story (PTCT)? - simplywall.st
Form 144 PTC THERAPEUTICS For: 6 July By Investing.com - Investing.com Canada
PTCT (NASDAQ) affiliate plans option exercise; director sold 10,522 shares - Stock Titan
All eyes on PTC Therapeutics earnings after brutal Q4 miss - Investing.com
Enterprise value to EBIT forward of PTC Therapeutics, Inc. – NASDAQ:PTCT - TradingView
PTC Therapeutics updates investors on rare disease pipeline as Nasdaq-listed biotech advances progra - AD HOC NEWS
Ptc therapeutics chief technical ops officer sells $693k in stock By Investing.com - Investing.com Australia
Ptc therapeutics chief technical ops officer sells $693k in stock - Investing.com Australia
Form 4 PTC Therapeutics Inc For: 30 June By Investing.com - Investing.com South Africa
Enterprise value to EBITDA forward of PTC Therapeutics, Inc. – NASDAQ:PTCT - TradingView
Price to sales forward of PTC Therapeutics, Inc. – NASDAQ:PTCT - TradingView
Enterprise value to revenue forward of PTC Therapeutics, Inc. – NASDAQ:PTCT - TradingView
PTC Therapeutics, Inc.(NasdaqGS: PTCT) added to Russell 2000 Value-Defensive Index - marketscreener.com
PTC Therapeutics, Inc.(NasdaqGS: PTCT) added to Russell 2000 Growth-Defensive Index - marketscreener.com
Price to earnings forward of PTC Therapeutics, Inc. – FWB:BH3 - TradingView
PTC Therapeutics, Inc.(NasdaqGS: PTCT) added to Russell 2000 Defensive Index - marketscreener.com
Understanding the Setup: (PTCT) and Scalable Risk - Stock Traders Daily
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Aga - The National Law Review
PTC Therapeutics (PTCT) Launches Sephience After Strong Early Sales And $500 Million Raise - Sahm
PTC Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Pauwels Eric - Moomoo
Ptc therapeutics chief technical ops officer sells $2.25m in stock - Investing.com South Africa
Form 144 PTC THERAPEUTICS For: 26 June By Investing.com - Investing.com South Africa
Form 4 PTC Therapeutics Inc For: 26 June By Investing.com - Investing.com Australia
PTC Therapeutics (NASDAQ:PTCT) Insider Neil Gregory Almstead Sells 5,323 Shares - MarketBeat
PTC Therapeutics, Inc. Actuals & Estimates (NASDAQ:PTCT) - TradingView
Affiliate sale notice — PTCT (NASDAQ: PTCT) files to sell 8,130 shares - Stock Titan
PTC Therapeutics (NASDAQ:PTCT): What’s Driving the Latest Buzz? - Kalkine Media
PTC Therapeutics Inc (PTCT) Stock Forecast, Price Targets and Analysts Predictions - GuruFocus
Form 144 PTC THERAPEUTICS For: 25 June By Investing.com - Investing.com Nigeria
PTCT Forecast — Price Target — Prediction for 2027 - TradingView
Huntington's Disease Market Poised for Significant Growth at a CAGR of 14% During the Forecast Period (2026-2036) Amid Advancements in Disease-Modifying Therapies | DelveInsight - Yahoo Finance Singapore
Form 144 PTC THERAPEUTICS For: 24 June By Investing.com - Investing.com South Africa
Form 4 PTC Therapeutics Inc For: 24 June By Investing.com - Investing.com India
Ptc therapeutics chief technical ops officer sells $1.92m in stock By Investing.com - Investing.com Australia
Ptc therapeutics chief technical ops officer sells $1.92m in stock - Investing.com Nigeria
PTC 테라퓨틱스 (PTCT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.18%
2.48%
자본화:
|
볼륨(24시간):